Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1

  • raised blood eosinophils (EOS)
  • and/or raised fraction of exhaled nitric oxide (FeNO),
  • who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

An extensive clinical trial programme

  • ADULTS AND ADOLESCENTS:
    DUPIXENT was studied in one Phase 2b and two Phase 3 clinical trials including 2,888 patients aged 12 years and older, for up to 52 weeks1

INTRODUCING THE DUPIXENT PRE-FILLED PEN

DUPIXENT can be administered via
a pre-filled pen or a syringe1

References

  1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.